0.94
-7.84%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Aelis Farma
Its shares trade on Euronext Paris under the ticker AELIS.PA. It has been listed since 18 February 2022. In the fiscal year to 31 December 2025, it reported revenue of €2.1m and a net loss of €6.4m. At that date it held total assets of €12.0m and shareholders' equity of €4.4m.
Aelis Farma SA engages in the research and development of pharmaceutical products. The company is headquartered in Bordeaux, Nouvelle-Aquitaine. The company went IPO on 2022-02-18. The firm provides two products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis, and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome). The company offers viable treatments for certain pathological conditions linked to hyperactivity of the CB1 receptor, the main receptor of the endocannabinoid system. The company provides advanced drug AEF0117, to combat the harmful effects of cannabis and in particular Cannabis Use Disorders (CUD) which is the current definition of cannabis addiction in the diagnostic manual reference DSM-5. The firm operates a Research and Development (R&D) platform, which enables the Company to discover drug candidates that act as specific modulators of target receptor signaling.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 18 Feb 2022
- Employees
- 22
- Website
- aelisfarma.com ↗
Leadership
Pay as last reported
- Dr. Anders PedersenIndependent Chairman of the Board€473,614
- Dr. Pier Vincenzo PiazzaChief Executive Officer, Co-Founder, Director, since 2017€100,000
- Ms. Stephanie MonlezunCo-Founder, Chief Operating Officer
- Ms. Sandy FabreCo-Founder, Head - Discovery and IP Leader
- Ms. Marie Line LafevreHead - Finance
- Ms. Lea FloquetHead - Legal
- Ms. Aurelie BoucardHead - Preclinical Development
- Ms. Corinne ChaimbaultHead - Pharmaceutical Development
- Mr. Arsene GuekamChief Corporate Development Officer
- Ms. Helle MengelHead - Clinical Development
- Mr. M. Brahim GuetarniDirector, Representative of Nouvelle-Aquitaine Region
- Ms. Karina HansenIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Aelis Farma SA focuses on innovative biotechnology in Bordeaux, France.
- The company has two clinical-stage products: AEF0117 and AEF0217.
- Aelis Farma SA's R&D platform targets CB1 receptor modulation for cannabis disorders.
Weaknesses
- Aelis Farma SA employs only 22 full-time staff in Bordeaux.
- The company's IPO occurred in February 2022 with limited market presence.
- Aelis Farma SA's products are still in clinical development phase.
Opportunities
- Aelis Farma SA can expand its product portfolio in the Health Care sector.
- The growing demand for cannabis disorder treatments presents a market opportunity.
- Aelis Farma SA's CB1 receptor research aligns with emerging medical trends.
Threats
- Aelis Farma SA faces competition from established biotechnology firms in France.
- Regulatory challenges may delay clinical trials for AEF0117 and AEF0217.
- The biotechnology sector requires significant capital investment for product development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.